Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03718923 · ClinicalTrials.gov registry record
FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.
A clinical trial of Autism Spectrum Disorder and FOXP1, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT03718923 is a study of Autism Spectrum Disorder and FOXP1 that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 50 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03718923, a study of Autism Spectrum Disorder and FOXP1, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
FOXP1, also known as Forkhead-box Protein P1, is a transcription factor protein belonging to the FOX gene family. Disruptions in the FOXP1 gene cause a phenotype characterized by global developmental delay, speech deficits, mild dysmorphic features, and traits of autism spectrum disorder. This study seeks to characterize FOXP1-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.
Conditions Studied
Study Locations (1)
New York
- The Seaver Autism Center for Research and Treatment - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-03-28 |
| Est. Completion | 2026-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03718923
The ClinicalTrials.gov registry entry for NCT03718923 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (63% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT03718923 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03718923 about?
NCT03718923 is a clinical study titled "FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.". FOXP1, also known as Forkhead-box Protein P1, is a transcription factor protein belonging to the FOX gene family. Disruptions in the FOXP1 gene cause a phenotype characterized by global developmental delay, speech deficits, mild dysmorphic features, and traits of autism spectrum disorder. This study...
What is the current status of trial NCT03718923?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2016-03-28. Estimated completion is 2026-04.
What conditions does trial NCT03718923 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, FOXP1, Mental Retardation With Language Impairment and With or Without Autistic Features.
Who is sponsoring clinical trial NCT03718923?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03718923 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design
RECRUITING · Early Phase 1
-
Cannabidiol (CBD) in Adults With ASD
RECRUITING · Phase 1
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.